Table 4 Summary of efficacy after PSM in cohort 2 (Apatinib plus Chemotherapy vs. Chemotherapy Alone)

All comers, n

27

27

-

-

Objective response, n (%; 95% CI)

12 (44.4; 25.5–64.7)

3 (11.1; 2.4–29.2)

0.015

Disease control, n (%; 95% CI)

22 (81.5; 61.9–93.7)

6 (22.2; 8.6–42.5)

< 0.001

Progression-free survival, month (95% CI)

7.8 (6.4–13.0)

2.1 (2.0-3.3)

0.16 (0.08–0.32)

< 0.001

Overall survival, month (95% CI)

21.1 (15.5-NR)

9.0 (6.2–13.3)

0.16 (0.07–0.37)

< 0.001

1st line, n

6

6

-

Objective response, n (%; 95% CI)

5 (83.3; 35.9–99.6)

2 (33.3; 4.3–77.7)

0.242

Disease control, n (%; 95% CI)

6 (100.0)

2 (33.3; 4.3–77.7)

0.030

2^nd+line, n

21

21

-

Objective response, n (%; 95% CI)

7 (33.3; 14.6–57.0)

1 (4.8; 0.1–23.8)

0.049

Disease control, n (%; 95% CI)

16 (76.2; 52.8–91.8)

4 (19.0; 5.4–41.9)

0.001